Browse TNFRSF13C

Summary
SymbolTNFRSF13C
Nametumor necrosis factor receptor superfamily, member 13C
Aliases BAFFR; CD268; BAFF-R; BROMIX; CVID4; prolixin; B cell-activating factor receptor; B-cell-activating factor r ......
Chromosomal Location22q13.1-q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type III membrane protein
Domain PF09256 BAFF-R
Function

B-cell receptor specific for TNFSF13B/TALL1/BAFF/BLyS. Promotes the survival of mature B-cells and the B-cell response.

> Gene Ontology
 
Biological Process GO:0001776 leukocyte homeostasis
GO:0001782 B cell homeostasis
GO:0001819 positive regulation of cytokine production
GO:0002250 adaptive immune response
GO:0002260 lymphocyte homeostasis
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002467 germinal center formation
GO:0002634 regulation of germinal center formation
GO:0002636 positive regulation of germinal center formation
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002819 regulation of adaptive immune response
GO:0002821 positive regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0007159 leukocyte cell-cell adhesion
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030888 regulation of B cell proliferation
GO:0030890 positive regulation of B cell proliferation
GO:0031294 lymphocyte costimulation
GO:0031295 T cell costimulation
GO:0031296 B cell costimulation
GO:0032609 interferon-gamma production
GO:0032649 regulation of interferon-gamma production
GO:0032729 positive regulation of interferon-gamma production
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0033209 tumor necrosis factor-mediated signaling pathway
GO:0034612 response to tumor necrosis factor
GO:0042035 regulation of cytokine biosynthetic process
GO:0042089 cytokine biosynthetic process
GO:0042095 interferon-gamma biosynthetic process
GO:0042098 T cell proliferation
GO:0042100 B cell proliferation
GO:0042102 positive regulation of T cell proliferation
GO:0042107 cytokine metabolic process
GO:0042108 positive regulation of cytokine biosynthetic process
GO:0042110 T cell activation
GO:0042113 B cell activation
GO:0042129 regulation of T cell proliferation
GO:0045072 regulation of interferon-gamma biosynthetic process
GO:0045078 positive regulation of interferon-gamma biosynthetic process
GO:0045785 positive regulation of cell adhesion
GO:0046651 lymphocyte proliferation
GO:0048872 homeostasis of number of cells
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050863 regulation of T cell activation
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0050871 positive regulation of B cell activation
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0071356 cellular response to tumor necrosis factor
GO:0071593 lymphocyte aggregation
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
Molecular Function -
Cellular Component GO:0009897 external side of plasma membrane
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04064 NF-kappa B signaling pathway
hsa04672 Intestinal immune network for IgA production
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-5676594: TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
R-HSA-5668541: TNFR2 non-canonical NF-kB pathway
Summary
SymbolTNFRSF13C
Nametumor necrosis factor receptor superfamily, member 13C
Aliases BAFFR; CD268; BAFF-R; BROMIX; CVID4; prolixin; B cell-activating factor receptor; B-cell-activating factor r ......
Chromosomal Location22q13.1-q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TNFRSF13C and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolTNFRSF13C
Nametumor necrosis factor receptor superfamily, member 13C
Aliases BAFFR; CD268; BAFF-R; BROMIX; CVID4; prolixin; B cell-activating factor receptor; B-cell-activating factor r ......
Chromosomal Location22q13.1-q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TNFRSF13C in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTNFRSF13C
Nametumor necrosis factor receptor superfamily, member 13C
Aliases BAFFR; CD268; BAFF-R; BROMIX; CVID4; prolixin; B cell-activating factor receptor; B-cell-activating factor r ......
Chromosomal Location22q13.1-q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TNFRSF13C in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0450.928
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.5160.517
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3120.653
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0680.918
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6530.581
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.9820.466
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4980.394
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.9080.302
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2080.839
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0170.942
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TNFRSF13C in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTNFRSF13C
Nametumor necrosis factor receptor superfamily, member 13C
Aliases BAFFR; CD268; BAFF-R; BROMIX; CVID4; prolixin; B cell-activating factor receptor; B-cell-activating factor r ......
Chromosomal Location22q13.1-q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TNFRSF13C. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTNFRSF13C
Nametumor necrosis factor receptor superfamily, member 13C
Aliases BAFFR; CD268; BAFF-R; BROMIX; CVID4; prolixin; B cell-activating factor receptor; B-cell-activating factor r ......
Chromosomal Location22q13.1-q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TNFRSF13C. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TNFRSF13C.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTNFRSF13C
Nametumor necrosis factor receptor superfamily, member 13C
Aliases BAFFR; CD268; BAFF-R; BROMIX; CVID4; prolixin; B cell-activating factor receptor; B-cell-activating factor r ......
Chromosomal Location22q13.1-q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TNFRSF13C. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTNFRSF13C
Nametumor necrosis factor receptor superfamily, member 13C
Aliases BAFFR; CD268; BAFF-R; BROMIX; CVID4; prolixin; B cell-activating factor receptor; B-cell-activating factor r ......
Chromosomal Location22q13.1-q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TNFRSF13C expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTNFRSF13C
Nametumor necrosis factor receptor superfamily, member 13C
Aliases BAFFR; CD268; BAFF-R; BROMIX; CVID4; prolixin; B cell-activating factor receptor; B-cell-activating factor r ......
Chromosomal Location22q13.1-q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TNFRSF13C and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTNFRSF13C
Nametumor necrosis factor receptor superfamily, member 13C
Aliases BAFFR; CD268; BAFF-R; BROMIX; CVID4; prolixin; B cell-activating factor receptor; B-cell-activating factor r ......
Chromosomal Location22q13.1-q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TNFRSF13C collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.